Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice

Archives of Virology

Volumn 156, Issue 3, 2011, Pages 387-395

  Wu, Jian ^a   Wang, Fuyan ^a,b   Fang, Fang ^a   Zhang, Wenjie ^e   Chang, Haiyan ^a   Zheng, Liyun ^c   Chen, Ze ^a,c,d  

^a HUNAN NORMAL UNIVERSITY   (China)

^b The First People s Hospital of Changde City)   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; DISEASE MODEL; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; INSULIN DEPENDENT DIABETES MELLITUS; LUNG; MALE; METHODOLOGY; MOUSE; ORTHOMYXOVIRUS INFECTION; SURVIVAL; VACCINATION; VIROLOGY; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SQUALENE; SURVIVAL ANALYSIS; VACCINATION; VACCINES, INACTIVATED; VIRAL LOAD;

MUS; ORTHOMYXOVIRIDAE;

EID: 79952244565     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0860-4     Document Type: Article

References (48)

1. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P (2008) Cross-protection by MF59-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against a(H3N2) drifted influenza viruses. Vaccine 26:1525-1529
2. Baldo V, Baldovin T, Floreani A, Carraro A M, Trivello R (2007) MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25:3955-3961
3. Banzhoff A, Nacci P, Podda A (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity metaanalysis. Gerontology 49:177-184
4. Beigel J H, Farrar J, Han A M, Hayden F G, Hyer R, de Jong M D, Lochindarat S, Nguyen T K, Nguyen T H, Tran T H, Nicoll A, Touch S, Yuen K Y (2005) Avian influenza a (H5N1) infection in humans. N Engl J Med 353:1374-1385
5. Beyer W E, Palache A M, Osterhaus A D (1998) Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literature. Clin Drug Investig 15:1-12
6. Bresson J L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon M C (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367:1657-1664
7. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A (2008) Alum boosts Th2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26:2350-2359
8. Burke R L, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G (1994) The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 170:1110-1119
9. Cataldo D M, Van Nest G (1997) The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15:1710-1715
10. Chen QJ, Kuang HM, Wang HD, Fang F, Yang ZD, Zhang ZP, Zhang XE, Chen Z (2009) Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38:30-38
11. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A, Dowell S F (2005) Human disease from influenza a (H5N1), thailand, 2004. Emerg Infect Dis 11:201-209
12. Del Giudice G, Hilbert A K, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A (2006) An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24:3063-3065
13. Diepersloot R J, Bouter K P, Beyer WE, Hoekstra J B, Masurel N (1987) Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 30:397-401
14. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A (2001) Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 17:135-140
15. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A (2008) Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses 2:41-51
16. Geerlings S E, Hoepelman A I (1999) Immune dysfunction in patients with diabetes mellitus (dm). FEMS Immunol Med Microbiol 26:259-265
17. Hovden A O, Cox R J, Haaheim L R (2005) Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in Balb/c mice. Scand J Immunol 62:36-44
18. Huber V C, McKeon R M, Brackin M N, Miller L A, Keating R, Brown S A, Makarova N, Perez D R, Macdonald G H, McCullers J A (2006) Distinct contributions of vaccine-induced immunoglobulin g1 (IgG 1) and IgG 2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981-990
19. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665
20. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1) vaccine: A phase I randomised controlled trial. Lancet 368:991-997
21. McLaren C, Verbonitz M W, Daniel S, Grubbs G E, Ennis F A (1977) Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J Infect Dis 136 Suppl:S706-S711
22. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P (1999) Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17:99-104
23. Muller L M, Gorter K J, Hak E, Goudzwaard W L, Schellevis F G, Hoepelman A I, Rutten G E (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281-288
24. Nicholson K G, Tyrrell D A, Harrison P, Potter C W, Jennings R, Clark A, Schild G C, Wood J M, Yetts R, Seagroatt V, Huggins A, Anderson S G (1979) Clinical studies of monovalent inactivated whole virus and subunit A/Ussr/77 (H1N1) vaccine: Serological responses and clinical reactions. J Biol Stand 7:123-136
25. Ninomiya A, Imai M, Tashiro M, Odagiri T (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554-3560
26. Ott G, Barchfeld G L, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296
27. Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, Galli C, Corradini S G, Biasio L, Gale E A, Andreani D (1987) Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 30:817-819
28. Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Zhang R, Chen Z (2006) Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in Balb/c mice. Biochem Biophys Res Commun 343:1124-1131
29. Renegar K B, Small P A, Jr., Boykins L G, Wright P F (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978-1986
30. Smith S A, Poland G A (2003) Immunization and the prevention of influenza and pneumococcal disease in people with diabetes. Diabetes Care 26 Suppl 1:S126-S128
31. Smith S A, Poland G A (2004) Influenza and pneumococcal immunization in diabetes. Diabetes Care 27 Suppl 1:S111-S113
32. Stephenson I, Nicholson K G, Gluck R, Mischler R, Newman R W, Palache A M, Verlander N Q, Warburton F, Wood J M, Zambon M C (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial. Lancet 362:1959-1966
33. Szyszko E, Brokstad K, Cox R J, Hovden A O, Madhun A, Haaheim L R (2006) Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 64:467-475
34. Tamura S I, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A (1992) Superior crossprotective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22:477-481
35. Traquina P, Morandi M, Contorni M, Van Nest G (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 174:1168-1175
36. Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza a (H5N1) vaccine. N Engl J Med 354:1343-1351
37. Treanor J J, Wilkinson B E, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz J M (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737
38. Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I (2007) Inactivated whole virus influenza a (H5N1) vaccine. Emerg Infect Dis 13:807-808
39. Valensi J P, Carlson J R, Van Nest G A (1994) Systemic cytokine profiles in Balb/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153:4029-4039
40. van Riel D, Munster V J, de Wit E, Rimmelzwaan G F, Fouchier R A, Osterhaus A D, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399
41. Wack A, Baudner B C, Hilbert A K, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O'Hagan D T (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26:552-561
42. WHO. (accessed 06 May 2009.) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_09_24/en/index.html
43. WHO. (accessed Aug 17, 2006.) Development and evaluation of influenza pandemic vaccines: Report of who expert meeting. Initiative for vaccine research, global influenza programme. http://www.who.int/vaccine_research/documents/Report%20021105.pdf
44. WHO. WHO manual on animal influenza diagnosis and surveillance. (http://www.Who.Int/vaccine_research/diseases/influenza/who_manual_on_animal-diagnosis_and_surveillance_2002_5.Pdf), WH0, 2002.
45. Wright P F, Thompson J, Vaughn W K, Folland D S, Sell S H, Karzon D T (1977) Trials of influenza A/New Jersey/76 virus vaccine in normal children: An overview of age-related antigenicity and reactogenicity. J Infect Dis 136 Suppl:S731-S741
46. Wu J, Zhang F, Fang F, Chang H, Wang F, Yang Z, Sun B, Chen Z (2010) Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes. Vaccine 28:2775-2781
47. Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z (2009) A single immunization with ha DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 9:17
48. Zhu Q, Chang H, Chen Y, Fang F, Xue C, Zhang F, Qiu M, Wang H, Wang B, Chen Z (2005) Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochem Biophys Res Commun 329:87-94